CO2021011046A2 - Composición farmacéutica que comprende macitentán para el tratamiento de la hipertensión pulmonar tromboembólica crónica - Google Patents
Composición farmacéutica que comprende macitentán para el tratamiento de la hipertensión pulmonar tromboembólica crónicaInfo
- Publication number
- CO2021011046A2 CO2021011046A2 CONC2021/0011046A CO2021011046A CO2021011046A2 CO 2021011046 A2 CO2021011046 A2 CO 2021011046A2 CO 2021011046 A CO2021011046 A CO 2021011046A CO 2021011046 A2 CO2021011046 A2 CO 2021011046A2
- Authority
- CO
- Colombia
- Prior art keywords
- macitentan
- treatment
- aprocitentan
- cteph
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con dosis elevadas de macitentán (INN), es decir, ácido propilsulfámico [5-(4-bromo-fenil)-6-[2-(5-bromo-pirimidin-2-iloxi)-etoxi]-pirimidin-4-il]-amida o sales farmacéuticamente aceptables, solvatos, hidratos o formas morfológicas de este, o de aprocitentán, para uso en el tratamiento y/o la prevención de la hipertensión pulmonar tromboembólica crónica (HPTEC). Además, la presente invención se relaciona con el uso de dosis elevadas de macitentán o de aprocitentán para la elaboración de un medicamento para el tratamiento y/o la prevención de la HPTEC, así como con un método para el tratamiento y/o la prevención de la HPTEC que comprende administrar dosis elevadas de macitentán o de aprocitentán a un paciente. Adicionalmente, la presente invención se relaciona con un régimen de dosificación para el tratamiento y/o la prevención de la HAP así como con una combinación de macitentán, o de aprocitentán, con uno o más inhibidores de la fosfodiesterasa tipo 5 (PDE5), análogos de prostaciclina, agonistas del receptor de prostaciclina o estimuladores de la guanilato ciclasa solubles. Además, la presente invención se relaciona con una composición farmacéutica para el tratamiento de la HPTEC que comprende una dosis elevada de macitentán o de aprocitentán.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019051874 | 2019-01-25 | ||
| EP2019060152 | 2019-04-18 | ||
| EP2019066495 | 2019-06-21 | ||
| EP2019067187 | 2019-06-27 | ||
| PCT/EP2020/051707 WO2020152308A1 (en) | 2019-01-25 | 2020-01-24 | Pharmaceutical composition comprising macitentan for the treatment of chronic thromboembolic pulmonary hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021011046A2 true CO2021011046A2 (es) | 2022-01-17 |
Family
ID=69177170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0011046A CO2021011046A2 (es) | 2019-01-25 | 2021-08-23 | Composición farmacéutica que comprende macitentán para el tratamiento de la hipertensión pulmonar tromboembólica crónica |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20220096474A1 (es) |
| EP (1) | EP3914253A1 (es) |
| JP (1) | JP2022522612A (es) |
| KR (1) | KR20210120024A (es) |
| CN (1) | CN113329751A (es) |
| AU (1) | AU2020211014A1 (es) |
| BR (1) | BR112021014499A2 (es) |
| CA (1) | CA3127271A1 (es) |
| CL (1) | CL2021001933A1 (es) |
| CO (1) | CO2021011046A2 (es) |
| IL (1) | IL284988A (es) |
| JO (1) | JOP20210198A1 (es) |
| MA (1) | MA54809A (es) |
| MX (1) | MX2021008574A (es) |
| SG (1) | SG11202106312SA (es) |
| TW (1) | TW202042818A (es) |
| WO (1) | WO2020152308A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019410727A1 (en) | 2018-12-21 | 2021-08-12 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition for the treatment of pulmonary arterial hypertension |
| TW202042818A (zh) * | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4245130B2 (ja) | 2000-12-18 | 2009-03-25 | アクテリオン ファーマシューティカルズ リミテッド | 新規なスルファミド類 |
| AU2006290309B2 (en) | 2005-09-12 | 2012-04-05 | Actelion Pharmaceuticals Ltd. | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| PL2315587T3 (pl) | 2008-08-13 | 2018-03-30 | Actelion Pharmaceuticals Ltd. | Kompozycje terapeutyczne zawierające macitentan |
| EP3538154A1 (en) | 2016-11-10 | 2019-09-18 | Arena Pharmaceuticals, Inc. | Methods of treating pah with combinations of ralinepag and other agents |
| WO2018153925A1 (en) * | 2017-02-22 | 2018-08-30 | Amneal Pharmaceuticals Company Gmbh | Stable pharmaceutical compositions comprising macitentan |
| MA49664A (fr) | 2017-02-27 | 2020-06-03 | Idorsia Pharmaceuticals Ltd | Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline |
| AU2019410727A1 (en) * | 2018-12-21 | 2021-08-12 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition for the treatment of pulmonary arterial hypertension |
| TW202042818A (zh) * | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| TW202103703A (zh) | 2019-04-05 | 2021-02-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療門脈肺高血壓之方法 |
| CN114727951A (zh) | 2019-11-26 | 2022-07-08 | 埃科特莱茵药品有限公司 | 用于治疗房坦姑息术后患者中的肺血管疾病和/或心功能障碍的药物组合物 |
-
2020
- 2020-01-22 TW TW109102673A patent/TW202042818A/zh unknown
- 2020-01-24 JP JP2021542147A patent/JP2022522612A/ja active Pending
- 2020-01-24 SG SG11202106312SA patent/SG11202106312SA/en unknown
- 2020-01-24 CA CA3127271A patent/CA3127271A1/en active Pending
- 2020-01-24 MA MA054809A patent/MA54809A/fr unknown
- 2020-01-24 BR BR112021014499-4A patent/BR112021014499A2/pt unknown
- 2020-01-24 WO PCT/EP2020/051707 patent/WO2020152308A1/en unknown
- 2020-01-24 JO JOP/2021/0198A patent/JOP20210198A1/ar unknown
- 2020-01-24 MX MX2021008574A patent/MX2021008574A/es unknown
- 2020-01-24 CN CN202080010613.7A patent/CN113329751A/zh active Pending
- 2020-01-24 KR KR1020217026476A patent/KR20210120024A/ko not_active Application Discontinuation
- 2020-01-24 EP EP20701195.8A patent/EP3914253A1/en not_active Withdrawn
- 2020-01-24 US US17/425,576 patent/US20220096474A1/en active Pending
- 2020-01-24 AU AU2020211014A patent/AU2020211014A1/en not_active Abandoned
-
2021
- 2021-07-20 IL IL284988A patent/IL284988A/en unknown
- 2021-07-22 CL CL2021001933A patent/CL2021001933A1/es unknown
- 2021-08-23 CO CONC2021/0011046A patent/CO2021011046A2/es unknown
-
2022
- 2022-05-04 US US17/736,434 patent/US11612600B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3127271A1 (en) | 2020-07-30 |
| SG11202106312SA (en) | 2021-07-29 |
| MA54809A (fr) | 2022-04-20 |
| JOP20210198A1 (ar) | 2023-01-30 |
| AU2020211014A1 (en) | 2021-09-16 |
| MX2021008574A (es) | 2021-08-11 |
| BR112021014499A2 (pt) | 2021-09-28 |
| CL2021001933A1 (es) | 2022-04-08 |
| CN113329751A (zh) | 2021-08-31 |
| WO2020152308A1 (en) | 2020-07-30 |
| TW202042818A (zh) | 2020-12-01 |
| JP2022522612A (ja) | 2022-04-20 |
| IL284988A (en) | 2021-09-30 |
| KR20210120024A (ko) | 2021-10-06 |
| EP3914253A1 (en) | 2021-12-01 |
| US20220096474A1 (en) | 2022-03-31 |
| US11612600B2 (en) | 2023-03-28 |
| US20220331319A1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021007186A2 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
| CO2021011046A2 (es) | Composición farmacéutica que comprende macitentán para el tratamiento de la hipertensión pulmonar tromboembólica crónica | |
| PH12019502052A1 (en) | Hepatitis b virus surface antigen inhibitor | |
| CO2022008730A2 (es) | Composición farmacéutica para el tratamiento de la enfermedad vascular pulmonar y/o disfunción cardíaca en pacientes paliados con fontan | |
| CL2022000033A1 (es) | Composición farmacéutica para suministro nasal | |
| HRP20210624T1 (hr) | Režimi doziranja amisulprida za liječenje mučnine i povraćanja | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| MX2019011620A (es) | Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
| CL2019003533A1 (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| ECSP14028814A (es) | Nueva forma de dosificación y formulación de abediterol | |
| PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
| AR119679A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión pulmonar tromboembólica crónica | |
| AR115293A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
| DOP2022000004A (es) | Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad | |
| EA202192062A1 (ru) | Фармацевтическая композиция, содержащая мацитентан, для лечения хронической тромбоэмболической легочной гипертензии | |
| AR105087A1 (es) | Métodos para el tratamiento de mujeres con trastorno de deseo sexual hipoactivo (hsdd) con el tratamiento de combinación bupropión y trazodona | |
| EA202191733A1 (ru) | Фармацевтическая композиция для лечения легочной артериальной гипертензии | |
| CR20190401A (es) | Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas | |
| MX2021014194A (es) | Derivados de piridopirimidina y composiciones farmacéuticas, para su uso para prevenir o tratar enfermedades relacionadas con pi3 cinasa, que comprenden los mismos como principio activo. | |
| BR112022007623A2 (pt) | Composições para prevenir ou tratar doenças pulmonares obstrutivas crônicas (dpoc) | |
| BR112021024099A2 (pt) | Composição farmacêutica para diabetes mellitus | |
| TR201700073A2 (tr) | Di̇yabeti̇n tedavi̇si̇ i̇çi̇n terapöti̇k formülasyonlar | |
| UA109243U (uk) | Тверда лікарська форма, що містить інгібітор віл протеази |